Sage Therapeutics (NASDAQ: SAGE) today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Sage Therapeutics (SAGE) ~45% Upside Does Not Nearly Reflect Potential Market Opportunity - RBCJanuary 7, 2019 1:03 PM SAGE Therapeutics (SAGE) 'Hits It Out of the Park' with SAGE-217 Data - CowenJanuary 7, 2019 11:56 AM Sage Therapeutics (SAGE) SAGE-217 Ph3 Data 'Very Impressive' - BMOJanuary 7, 2019 11:52 AM Sage Therapeutics (SAGE) PT Raised to $90 at Leerink PartnersJanuary 7, 2019 11:48 AM SAGE Therapeutics (SAGE) Surges on Positive SAGE-217 Phase 3 DataJanuary 7, 2019 8:14 AM Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum DepressionJanuary 7, 2019 6:00 AM Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBCJanuary 3, 2019 3:59 PM Celgene, TESARO Deals Positive for SMID Cap Biotech - SunTrustJanuary 3, 2019 10:34 AM